Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low Levels of LRFN5 and OLFM4 in Schizophrenia May Be Associated With Synaptic Regulation and Immunoinflammatory Abnormalities

NCT07434388 is registered in ClinicalTrials.gov with Elazığ Mental Health and Diseases Hospital as lead sponsor.

NCT NCT07434388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07434388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low Levels of LRFN5 and OLFM4 in Schizophrenia May Be Associated With Synaptic Regulation and Immunoinflammatory Abnormalities
Lead sponsor
Elazığ Mental Health and Diseases Hospital
Phase
Observational
Overall status
Completed
Start date
April 27, 2025
Completion date
December 1, 2025
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia disorder